Table 1.

Pharmacological inhibition of FGFR4 does not improve kidney function or blood pressure in 5/6 nephrectomized rats. Analyses of renal and metabolic parameters as well as blood pressure in 5/6 nephrectomized (Nx) rats that were performed one week before surgery (baseline), four weeks after surgery (pre) and four weeks after initiation of treatment (post). Compared with 5/6Nx rats receiving vehicle solution, impaired renal function, hypertension, and elevated serum FGF23 levels are not significantly changed by delivery of a FGFR4-specific blocking antibody (anti-FGFR4). Values are reported as mean ± SEM; *p < 0.05 when compared to baseline 5/6Nx + vehicle; ^#p < 0.05 when compared to baseline 5/6Nx + anti-FGFR4.

		5/6Nx + vehicle	5/6Nx + anti-FGFR4
Creatinine clearance (ml/min/100 g)	baseline	0.79 ± 0.03	0.95 ± 0.02
	pre	0.28 ± 0.04*	0.32 ± 0.04#
	post	0.25 ± 0.04*	0.31 ± 0.05#
Blood urea nitrogen (mg/dl)	baseline	12 ± 0.8	15.7 ± 1.1
	pre	39.2 ± 3.8*	34.3 ± 3.5#
	post	39.3 ± 3.3*	37.5 ± 5.6#
Systolic blood pressure (mmHg)	baseline	141.7 ± 2.9	141.7 ± 5.5
	pre	206.7 ± 6.3*	216.7 ± 5.0#
	post	209.1 ± 5.5*	206.8 ± 7.5#
Diastolic blood pressure (mmHg)	baseline	100.3 ± 3.7	98.8 ± 4.9
	pre	150.6 ± 11.4*	166.8 ± 5.4#
	post	153.2 ± 10.6*	160 ± 9.3#
Urine protein (mg/mg creatinine)	baseline	2.79 ± 0.28	2.28 ± 0.28
	pre	15.12 ± 4.72*	13.52 ± 4.38#
	post	20.34 ± 5.75*	15.55 ± 4.78#
Phosphate (mg/dl)	post	5.94 ± 0.49	7.22 ± 0.58
FGF23 (pg/ml)	post	333 ± 119	485 ± 133